Back

The LUNAR-HF Trial: a randomised comparison of inclisiran versus evolocumab in ischaemic heart failure with reduced ejection fraction

30 August 2026 (12:12 - 12:24)
Organised by: Logo
Congress Presentation Part of: Optimising pharmacotherapy in heart failure Lipid-Lowering Agents ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Rafael Rascon Sabido

Mexican Institute of Social Security (IMSS), Veracruz (Mexico)

4 More presentations in this session

Presentation thumbnail
Evaluation of machine learning framework for personalized prediction of benefit from beta-blockers in myocardial infarction with preserved or mildly reduced ejection fraction
Doctor Y. Chen (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Simultaneous versus sequential initiation of CKM therapies: an indirect comparison of CONFIDENCE and FIDELITY
Doctor J. Ostrominski (Boston, US)
Abstract Slides Video
Presentation thumbnail
Finerenone-related initial declines in eGFR and urinary biomarkers of tubular injury: mechanistic insights from the FIVE-STAR trial
Doctor M. Vaduganathan (Boston, US)
Abstract Slides Video
Presentation thumbnail
Finerenone and serum sodium in patients with heart failure and mildly reduced or preserved ejection fraction: an analysis of FINEARTS-HF
Doctor R. Ono (Glasgow, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Optimising pharmacotherapy in heart failure
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 12:12 CET
You may be interested in
thumbnail
Congress Presentation
Head-to-head comparison of inclisiran vs bempedoic acid for LDL C lowering in patients with high and very high cardiovascular risk: Results from the phase 4 VICTORION-CHALLENGE trial
31 August 2026
thumbnail
Congress Session
Advances in heart failure detection and therapy
10 May 2026
thumbnail
Congress Presentation
Evolocumab and risk of a first myocardial infarction: a prespecified analysis of the VESALIUS-CV trial
28 August 2026
thumbnail
Congress Session
Smaller trials, trial updates, and other studies on lipid therapy
2 September 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources